Clinical Data AZ claims another win for Imfinzi in frontline liver cancer PharmaphorumAstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.Clinical DataOncologyRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesityNext: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
